---

---

positive   entities : Biogen inc.   

save search

---

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K |

Health Technology

| -7.5% | O: 0.25% H: 2.95% C: 2.88%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -12.63% | O: 0.43% H: 1.06% C: -0.05%
qalsody first chmp genetic positive treat therapy

---

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Published: 2023-12-15 (Crawled : 14:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -24.23% | O: 0.31% H: 0.98% C: -3.58%
skyclarys rare first disease chmp positive treat neurodegenerative therapy

---

The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
Published: 2022-09-07 (Crawled : 22:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -3.13% | O: 0.24% H: 3.43% C: 3.39%
biib059 lupus positive phase 2

---

The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -8.71% | O: -0.26% H: 1.35% C: 0.87%
biib059 lupus positive phase 2

---

Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
Published: 2022-06-03 (Crawled : 15:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -0.74% | O: 1.16% H: 3.3% C: 1.27%
solutions biosimilar positive phase 3

---

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Published: 2021-12-01 (Crawled : 12:30) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M |

Health Technology

| -65.47% | O: 1.76% H: 0.51% C: -5.42%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -17.8% | O: 0.21% H: 1.1% C: -3.16%
ongoing therapeutics positive

---

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Published: 2021-09-16 (Crawled : 11:33) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -35.04% | O: 0.53% H: 0.71% C: -0.37%
phase 2 positive results topline

---

Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
Published: 2021-07-26 (Crawled : 21:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K |

Health Technology

| 8.71% | O: 0.05% H: 1.28% C: -2.86%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -41.44% | O: 0.04% H: 0.73% C: 0.57%
disease alzheimer treatment positive topline alzheimer’s alzheimer's disease alzheimer's

---

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™
Published: 2021-06-25 (Crawled : 12:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -44.33% | O: -0.14% H: 1.41% C: -0.21%
positive chmp biosimilar

---

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Published: 2021-06-15 (Crawled : 11:00) - globenewswire.com
SAGE | $13.35 2.42% 2.36% 1.3M |

Health Technology

| -81.7% | O: -10.79% H: 3.81% C: -9.54%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -52.14% | O: -0.65% H: 1.71% C: -1.84%
positive results phase 3 depression major depressive disorder

---

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)
Published: 2021-06-01 (Crawled : 12:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -27.33% | O: 1.82% H: 0.0% C: -1.91%
positive results positive results phase 3 biosimilar

---

Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
Published: 2021-05-12 (Crawled : 12:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -30.18% | O: -0.44% H: 1.27% C: -1.14%
stroke phase 2 positive drug phase 2b

---

New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
Published: 2021-04-16 (Crawled : 12:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -28.12% | O: 0.06% H: 1.19% C: -0.11%
multiple sclerosis treatment positive sclerosis

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---